Technical Data
CA19-9 Cancer Antigen (Pancreatic, GI or Ovarian Tumor Antigen, Sialyl Lewis a)
Sialyl Lea is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lea and/or Leb blood group antigens.

Epitope: Sialic acid-containing residue of the monosialoganglioside (3).

Immunohistology (Formalin/paraffin): (Use Ab at 1:10-1:20 for 30 min at RT) No special pretreatment is required for staining of formalin-fixed, paraffin-embedded tissues.

Positive Control: Colon carcinoma.

Cellular Localization: Cell membrane

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and add glycerol (40-50%). Store at -20C or colder. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
500ul-20CBlue IceHumanMouse
Not determined
Human colon carcinoma cell line SW11162.
Culture supernatant
Supplied as a liquid with 0.09% sodium azide.
Reacts with sialylated Lea-active pentasaccharide (sialylated lacto-N-fucopentose II). Recognizes the sialic acid-containing residue of the monosialoganglioside. Removal of the sialic acid residue with neuraminidase treatment eliminates positive reactivity with this antibody. Species Crossreactivity: Human.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Hanai N, et al. (1990) Anti Canc Res, 10:1579.
2. Kaprowski H, et al. (1979) Somatic Cell Genet, 5:957.
3. Magnani J L, et al. (1882) J Biol Chem, 257:14635.
4. Atkinson B F, et al. (1982) Canc res, 42:4820.